Premium
Activin induces cell death in hepatocytes in vivo and in vitro
Author(s) -
Schwall Ralph H.,
Robbins Kim,
Jardieu Paula,
Chang Ling,
La Cora,
Terrel Timothy G.
Publication year - 1993
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840180219
Subject(s) - follistatin , transforming growth factor , activin type 2 receptors , endocrinology , medicine , in vivo , transforming growth factor beta , programmed cell death , growth factor , fragmentation (computing) , biology , acvr2b , tgf beta signaling pathway , apoptosis , chemistry , receptor , biochemistry , ecology , microbiology and biotechnology
While studying endocrine responses to activin in female rats, we discovered that activin caused a marked reduction in liver mass. The regressed livers exhibited no gross signs of necrosis or infarction, but histopathological evaluation revealed extensive cell death in the centrilobular regions. The dying cells appeared to fragment into structures resembling apoptotic bodies. Liver mass and histological appearance were restored after cessation of activin infusion, indicating that on an organ level, this effect was reversible. To determine whether the effects observed in vivo were caused by direct actions on the liver, we then tested activin on isolated hepatocytes in serum‐free medium. Under these conditions, activin caused many hepatocytes to undergo fragmentation, which was accompanied by a loss of 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT)–reducing activity, an index of viability. We compared the effects of activin with those of transforming growth factor‐β because activin is structurally related to transforming growth factor‐β and because transforming growth factor‐β has been shown previously to induce cell death in hepatocytes. Both proteins caused cell death of comparable magnitude, as defined by the extent of loss of MTT‐reducing activity, but transforming growth factor‐β was active at one tenth of the effective activin concentrations. A neutralizing monoclonal antibody to transforming growth factor‐β blocked the response to transforming growth factor‐β but had no effect on the response to activin. Conversely, follistatin, an activinbinding protein, blocked the response to activin but not to transforming growth factor‐β. Inhibin, which antagonizes the effects of activin in many systems, had little effect on the response to activin. Activin and transforming growth factor‐β differed in their onset of action; exposure to transforming growth factor‐β for only 1 hr induced a maximal response, whereas maximal response to activin required its continuous presence for 24 hr. These results show a novel effect of activin on cell death in hepatocytes in vivo and in vitro , suggesting that activin may have a previously unrecognized role in regulating hepatic function. (H EPATOLOGY 1993;18:347–356).